These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 28961280)
1. Label-free analysis of tenofovir delivery to vaginal tissue using co-registered confocal Raman spectroscopy and optical coherence tomography. Chuchuen O; Maher JR; Henderson MH; Desoto M; Rohan LC; Wax A; Katz DF PLoS One; 2017; 12(9):e0185633. PubMed ID: 28961280 [TBL] [Abstract][Full Text] [Related]
2. Full depth measurement of tenofovir transport in rectal mucosa using confocal Raman spectroscopy and optical coherence tomography. Presnell AL; Chuchuen O; Simons MG; Maher JR; Katz DF Drug Deliv Transl Res; 2018 Jun; 8(3):843-852. PubMed ID: 29468424 [TBL] [Abstract][Full Text] [Related]
3. Vaginal deployment and tenofovir delivery by microbicide gels. Gao Y; Yuan A; Chuchuen O; Ham A; Yang KH; Katz DF Drug Deliv Transl Res; 2015 Jun; 5(3):279-94. PubMed ID: 25874971 [TBL] [Abstract][Full Text] [Related]
4. Label-Free Measurements of Tenofovir Diffusion Coefficients in a Microbicide Gel Using Raman Spectroscopy. Chuchuen O; Maher JR; Simons MG; Peters JJ; Wax AP; Katz DF J Pharm Sci; 2017 Feb; 106(2):639-644. PubMed ID: 27837968 [TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of microbicide concentrations in fluids, gels and tissues using confocal Raman spectroscopy. Chuchuen O; Henderson MH; Sykes C; Kim MS; Kashuba AD; Katz DF PLoS One; 2013; 8(12):e85124. PubMed ID: 24386455 [TBL] [Abstract][Full Text] [Related]
6. Sensitivity Analysis of a Pharmacokinetic Model of Vaginal Anti-HIV Microbicide Drug Delivery. Jarrett AM; Gao Y; Hussaini MY; Cogan NG; Katz DF J Pharm Sci; 2016 May; 105(5):1772-1778. PubMed ID: 27012224 [TBL] [Abstract][Full Text] [Related]
7. Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel. Gao Y; Katz DF PLoS One; 2013; 8(9):e74404. PubMed ID: 24040241 [TBL] [Abstract][Full Text] [Related]
8. Semi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro. Lai BE; Geonnotti AR; Desoto MG; Montefiori DC; Katz DF Antiviral Res; 2010 Nov; 88(2):143-51. PubMed ID: 20709109 [TBL] [Abstract][Full Text] [Related]
9. Deducing Mucosal Pharmacokinetics and Pharmacodynamics of the Anti-HIV Molecule Tenofovir from Measurements in Blood. Govil S; Katz DF Sci Rep; 2019 Jan; 9(1):82. PubMed ID: 30643165 [TBL] [Abstract][Full Text] [Related]
10. Increased Dapivirine tissue accumulation through vaginal film codelivery of dapivirine and Tenofovir. Akil A; Devlin B; Cost M; Rohan LC Mol Pharm; 2014 May; 11(5):1533-41. PubMed ID: 24693866 [TBL] [Abstract][Full Text] [Related]
11. Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery system. Machado A; Cunha-Reis C; Araújo F; Nunes R; Seabra V; Ferreira D; das Neves J; Sarmento B Acta Biomater; 2016 Oct; 44():332-40. PubMed ID: 27544812 [TBL] [Abstract][Full Text] [Related]
12. Compartmental transport model of microbicide delivery by an intravaginal ring. Geonnotti AR; Katz DF J Pharm Sci; 2010 Aug; 99(8):3514-21. PubMed ID: 20222027 [TBL] [Abstract][Full Text] [Related]
13. Maximized mucoadhesion and skin permeation of anti-AIDS-loaded niosomal gels. Zidan AS; Habib MJ J Pharm Sci; 2014 Mar; 103(3):952-64. PubMed ID: 24464823 [TBL] [Abstract][Full Text] [Related]
14. Nanoparticles-in-film for the combined vaginal delivery of anti-HIV microbicide drugs. Cunha-Reis C; Machado A; Barreiros L; Araújo F; Nunes R; Seabra V; Ferreira D; Segundo MA; Sarmento B; das Neves J J Control Release; 2016 Dec; 243():43-53. PubMed ID: 27664327 [TBL] [Abstract][Full Text] [Related]
15. Reformulated tenofovir gel for use as a dual compartment microbicide. Dezzutti CS; Rohan LC; Wang L; Uranker K; Shetler C; Cost M; Lynam JD; Friend D J Antimicrob Chemother; 2012 Sep; 67(9):2139-42. PubMed ID: 22581908 [TBL] [Abstract][Full Text] [Related]
16. Transport theory for HIV diffusion through in vivo distributions of topical microbicide gels. Lai BE; Henderson MH; Peters JJ; Walmer DK; Katz DF Biophys J; 2009 Nov; 97(9):2379-87. PubMed ID: 19883580 [TBL] [Abstract][Full Text] [Related]
18. Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel. Thurman AR; Chandra N; Yousefieh N; Kimble T; Anderson SM; Cottrell M; Sykes C; Kashuba A; Schwartz JL; Doncel GF J Acquir Immune Defic Syndr; 2018 May; 78(1):82-92. PubMed ID: 29424790 [TBL] [Abstract][Full Text] [Related]
19. A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study). Mcgowan I; Cranston RD; Duffill K; Siegel A; Engstrom JC; Nikiforov A; Jacobson C; Rehman KK; Elliott J; Khanukhova E; Abebe K; Mauck C; Spiegel HM; Dezzutti CS; Rohan LC; Marzinke MA; Hiruy H; Hendrix CW; Richardson-Harman N; Anton PA PLoS One; 2015; 10(5):e0125363. PubMed ID: 25942472 [TBL] [Abstract][Full Text] [Related]
20. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial. Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]